Authorization

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.

On the drug approval front, Provention Bio, Inc. (NASDAQ:PRVB) faced a setback, as its diabetes drug failed to get the FDA nod. The stock shed over 20% in reaction to the adverse outcome. Expectedly, the review period for ChemoCentryx, Inc.'s (NASDAQ:CCXI) avacopan as a treatment option for small blood vessel damage was extended. The stock reacted positively to the outcome.

Alector, Inc. (NASDAQ:ALEC) was among the biggest gainers of the week, buoyed by an immuno-neurology deal it struck with GlaxoSmithKline plc (NYSE:GSK).

Biogen, Inc. (NASDAQ:BIIB) was under the scanner as the FDA narrowed the Aduhelm label and also called for an investigation into the interactions between FDA staffers and the company in the run-up to the approval.

Here are the key catalytic events that can impact trading in biotech stocks in the unfolding week:
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031